Prognostic impact of FOXF1 polymorphisms in gastric cancer patients. - PubMed - NCBI
Prognostic impact of FOXF1 polymorphisms in gastric cancer patients.
Matsusaka S1,
Wu AH2,
Cao S1,
Hanna DL1,
Chin K3,
Yang D1,
Zhang W1,
Ning Y1,
Stintzing S1,
Sebio A1,
Sunakawa Y1,
Stremitzer S1,
Yamauchi S1,
Okazaki S1,
Berger MD1,
Parekh A1,
Miyamoto Y1,
Mizunuma N3,
Lenz HJ1.
Abstract
A recent genome-wide association study identified seven single-nucleotide polymorphisms (SNPs) in region 16q24, near the Forkhead box-F1 (FOXF1) gene, which confer susceptibility to esophageal adenocarcinoma. We examined whether these SNPs are associated with clinical outcomes in gastric cancer (GC) patients in Japan and the United States. A total of 362 patients were included in this study: 151 Japanese GC patients treated with first-line S1 plus CDDP (training cohort) and 211 GC patients from Los Angeles County (LAC; validation cohort). Genomic DNA was isolated from whole blood or tumor tissue and analyzed by PCR-based direct DNA sequencing. Cox proportional hazard regression analyses were used to assess relationships between FOXF1 SNPs and progression-free survival (PFS) and overall survival (OS). FOXF1 rs3950627 was significantly associated with survival in both the training and validation cohorts. Japanese patients with the C/C genotype had a longer PFS (median 8.2 vs 5.3 months, hazard ratio (HR) 1.44, P=0.037) and OS (median 16.4 vs 12.2 months, HR 1.44, P=0.043) compared to patients with any A allele. Similarly, LAC patients with the C/C genotype had improved OS (3.9 vs 2.3 years, HR 1.5, P=0.022). Subgroup analyses showed these associations were specific to male patients and primary tumor subsite. Our findings suggest that FOXF1 rs3950627 might be a promising prognostic marker in GC patients.The Pharmacogenomics Journal advance online publication, 11 April 2017; doi:10.1038/tpj.2017.9.
No hay comentarios:
Publicar un comentario